Two NICE technology appraisals have now opened the door to the use of two new drugs
Two NICE technology appraisals have now opened the door to the use of larotrectinib or entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children (larotrectinib only). Although NTRK fusions are present in only around 0.5% of sarcomas, in some conditions this is much higher, for example infantile fibrosarcoma (90-100%), and GIST without more common driver mutations (5-25%). NTRK testing is gradually being rolled out as part of the new genetic tumour screening by the Genomic Laboratory Hubs in England. Similar programmes are underway in Scotland, Wales, and Northern Ireland.